Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an Anti-colony stimulating factor 1 receptor antibody

The use of CSF-1R-binding antibodies effectively addresses the challenge of treating cGVHD-related bronchiolitis obliterans syndrome by inhibiting CSF-1R function, showing clinical activity and safety in patients with advanced disease and multiple prior treatments.

WO2024238787A1PCT designated stage expired Publication Date: 2024-11-21SYNDAX PHARMACEUTICALS INC

Patent Information

Application Number
PCT/US2024/029683
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-16
Publication Date
2024-11-21

Smart Images

  • Figure US2024029683_21112024_PF_FP_ABST
    Figure US2024029683_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides methods of treating chronic graft-versus-host disease (cGVHD)-related bronchiolitis obliterans syndrome using an antibody that binds to colony stimulating factor 1 receptor (CSF-1R).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Pharmaceutical formulation comprising antibodies which bind colony stimulating factor-1 receptor (CSF1R)

    US10039826B2

  • Antibody affinity engineering by serial epitope-guided complementarity replacement

    US20050008625A1

  • Identification and engineering of antibodies with variant Fc regions and methods of using same

    US20050037000A1

  • Synthetic antibody phage libraries

    US20050079574A1

  • Antibodies against human CSF-1r and uses thereof

    US20110165156A1

Cited By

  • Antibodies that bind to colony stimulating factor 1 receptor (CSF-1r) and uses thereof

    WO2026147868A1